[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-416410-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-416410-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","major-revision-version-130-of-the-european-aids-clinical-society-guidelines-2025-updated-hiv-12-prep-comorbidities-and-co-infections","Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025 - Updated HIV-1/2, PrEP, comorbidities and co-infections","","The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, reorganized into two parts covering HIV management and prevention, and then comorbidities and related topics. Version 13.0 specifies first-line adult regimens for HIV-1, introduces a new HIV-2 section with integrase-inhibitor–based triple therapy, expands PrEP to include long-acting injectable antiretrovirals, and updates drug–drug interaction guidance. Extensive revisions update co-infections, including HBV and opportunistic infections, incorporate new trial data, and add sections on transition to adult care, sleep health and unified substance use. Cancer, cardiovascular and metabolic, kidney and liver, mental health, travel and transplantation recommendations are also updated, including statin use.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/major-revision-version-130-of-the-european-aids-clinical-society-guidelines-2025-updated-hiv-12-prep-comorbidities-and-co-infections/416410/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/major-revision-version-130-of-the-european-aids-clinical-society-guidelines-2025-updated-hiv-12-prep-comorbidities-and-co-infections/416410.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What structural changes does EACS Version 13.0 introduce for the 2025 guidelines?","Question",{"text":63,"@type":64},"Version 13.0 reorganizes the guidelines into two parts: Part I focuses on HIV management and prevention of HIV and related infections, while Part II covers comorbidities and other relevant topics.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which first-line antiretroviral options are recommended for adults with HIV-1 in Version 13.0?",{"text":68,"@type":64},"For HIV-1, Version 13.0 recommends first-line regimens combining TDF or TAF with lamivudine or emtricitabine, together with dolutegravir, bictegravir, or doravirine; it also includes a dual therapy option of emtricitabine/lamivudine plus dolutegravir.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the 2025 update change PrEP recommendations?",{"text":72,"@type":64},"The PrEP section is updated to include long-acting injectable antiretrovirals.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},416410,1790672683,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","DOI: 10.1111/hiv.70120  \nORIGINAL ARTICLE  \nMajor revision version 13.0 of the European AIDS Clinical Society guidelines 2025  \nJuan Ambrosioni 1,2 | Laura I. Levi 3 | Jasmini Alagaratnam 4,5 |  \nAbiu Sempere 1 | Andrea Mastrangelo 6 | Paolo Paioni 7 | Cristina Mussini 8 | Catia Marzolini 9,10,11  | Susanne Dam Nielsen 12  | Charles Béguelin 13 | Steven Welch 14 | Anna Koval 15 | Luis Mendao 16 | Alasdair Bamford 17,18 | Alexandra Calmy 19 | Giovanni Guaraldi 8  | Cristiana Oprea 20 |  \nEsteban Martínez 1,2,21  | Jürgen K. Rockstroh 22  | The EACS Governing Board  \n1HIV Unit, Infectious Diseases Service, Hospital Clinic-Fundacio de recerca Clinic Barcelona – Institut de investigacions Biomediques August Pi i Sunyer, Barcelona, Spain  \n2CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain  \n3Department of Infectious and Tropical Diseases, APHP, University Hospital of Bicêtre, Le Kremlin-Bicêtre, France 4HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK  \n5Section of Virology, Department of Infectious Disease, Imperial College London, London, UK  \n6Allergology and Immunology Department, Centre Hospitalier Universitaire Vaudoise (CHUV), Lausanne, Switzerland 7Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland 8Infectious Diseases Clinic, University of Modena and Reggio Emilia, Modena, Italy  \n9Departments of Medicine and Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland 10Service of Clinical Pharmacology, University Hospital Lausanne and University of Lausanne, Lausanne, Switzerland 11Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK 12Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark  \n13Department of Infectious Disease Services, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland 14Department of Paediatrics, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK  \n15Infectious Diseases Department, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 16European AIDS Treatment Group, Brussels, Belgium  \n17Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK 18UCL Great Ormond Street Institute of Child Health, London, UK  \n19HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland  \n20Infectious Diseases and HIV Department, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania  \n21Reial Acadèmia de Medicina de Catalunya, Barcelona, Spain  \n22Department of Medicine I, Bonn University Hospital, Bonn, Germany  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2025 The Author(s) . HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.  \nCorrespondence  \nJuan Ambrosioni, HIV Unit, Infectious Disease Service, Hospital Clinic-Fundaci de recerca Clinic Barcelona – Institut de investigacions Biomediques August Pi i Sunyer, Villarroel 170, 08036, Barcelona, Spain.  \nEmail: [jambrosioni@intramed.net](jambrosioni@intramed.net)  \nAbstract  \nBackground: The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update: The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part II addresses comorbidities and other relevant topics. In Part I, Version 13.0 recommends the following first-line regimens for adults ","cbCaitPG3gH7M3Ms","https://ap.wps.com/l/cbCaitPG3gH7M3Ms","pdf",865543,15,"English","# Abstract\n## Key Points of the Guidelines Update\n## Conclusions","[{\"question\":\"What structural changes does EACS Version 13.0 introduce for the 2025 guidelines?\",\"answer\":\"Version 13.0 reorganizes the guidelines into two parts: Part I focuses on HIV management and prevention of HIV and related infections, while Part II covers comorbidities and other relevant topics.\"},{\"question\":\"Which first-line antiretroviral options are recommended for adults with HIV-1 in Version 13.0?\",\"answer\":\"For HIV-1, Version 13.0 recommends first-line regimens combining TDF or TAF with lamivudine or emtricitabine, together with dolutegravir, bictegravir, or doravirine; it also includes a dual therapy option of emtricitabine/lamivudine plus dolutegravir.\"},{\"question\":\"How does the 2025 update change PrEP recommendations?\",\"answer\":\"The PrEP section is updated to include long-acting injectable antiretrovirals.\"}]","Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025 - Updated HIV-1/2, PrEP, comorbidities and co-infections | PDF",1790605342,38]